91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Supporting reimbursement decisions with data from external control arms
Data is at the heart of every decision made by CROs, and so can have significant legal and financial implications. In this article 91黑料 experts weigh in on maximising the efficacy of data and ensuring the scientific rigour HTAs expect.
This article is taken from European Pharmaceutical Contractor, August 2022, pages 52-55. Samedan Ltd
-
Karen Johnstone and Sabine Richter discuss .
-
Outcomes researchers Alexia Marrel and Sally Lanar share insights on longitudinal qualitative research - what it is, when and how it can be used and the key factors for success when using this type of research.
-
features commentary from CEO Steve Cutler about 91黑料 being awarded 2021 Company of the Year.
-
The benefits of .
-
Will Maier, VP of Rare Diseases, shares how a more patient-focused approach to trials is leading to alternatives for randomisation.
-
This article focuses on what others could learn from good statistical practices in drug development and considers areas where drug development could benefit from some fresh thinking
-
Tim Clark, VP Drug Development Solutions and Alan Phillips, Sr. Director Biostatistics present a case study on the first in human Bayesian Optimal Interval design.
-
Steve Culter gives insight into 91黑料 as a company along with his thoughts on winning this award.
-
What Biotech and Pharma need to consider about decentralised trials
Discuss key considerations when implementing decentralised clinical trials, in addition to the success factors that lead to more patient-centric trials and increased patient recruitment, engagement and retention.
